Abstract

The prognostic significance of sCD86 in patients with hematologic malignancies is unclear. We evaluated sCD86 levels in 63 newly diagnosed AML and 16 controls by enzyme-linked immunosorbent assay and then analyzed how its levels and various clinical parameters related to overall survival. Levels of sCD86 in patients were high (1.22 ± 1.34) compared with the controls (0.51 ± 0.23) but were not significant (p = 0.096). The patients' outcome and whether they achieved complete remission and if they were sCD86 positive or negative didn't have any significance (p = 0.1). High levels of sCD86 were detected in patients with hypercellular marrow (with a high percentage of bone marrow blasts), FLT-3 mutated type, and in FAB M4-M5. The overall survival among sCD86-positive and sCD86-negative patients was not significant (p = 0.16). The overall survival of patients regarding clinical parameters showed no significance except for FLT-3 type (p = 0.001). Aim of the Study: The aim of the study is to assess the level of soluble CD86 (sCD86) in patients with de novo AML and to compare them with a normal control group to determine any possible role with prognosis and clinical outcome, as the significance of sCD86 in hematologic malignancies is still controversial.

Authors and Affiliations